nach oben

Erschienen in:

20.12.2022 | Substantive Review

Substance Use and Adherence to HIV Pre-Exposure Prophylaxis in Studies Enrolling Men Who Have Sex with Men and Transgender Women: A Systematic Review

verfasst von: Nioud Mulugeta Gebru, Shantrel S. Canidate, Yiyang Liu, Sage E. Schaefer, Emmely Pavila, Robert L. Cook, Robert F. Leeman

Erschienen in: AIDS and Behavior | Ausgabe 7/2023

Einloggen, um Zugang zu erhalten

Abstract

Optimal adherence to pre-exposure prophylaxis (PrEP) is critical, but challenging. Men who have sex with men and transgender women have high rates of HIV incidence and substance use. Substance use is associated with reduced adherence to other medications, but associations between substance use and adherence to PrEP are less clear. Thus, the current review 1) systematically evaluates the measurement of substance use and PrEP adherence in studies examining both and 2) summarizes reported findings. Peer-reviewed articles published between 2010 - April 2021 examining associations between substance use and PrEP adherence were reviewed. Fifty studies met inclusion criteria. Assessment of substance use (i.e., mostly via self-reports at baseline) and PrEP adherence (i.e., often via tenofovir diphosphate [TFV-DP] concentration levels at follow-up) varied considerably across studies. Many studies used categorical variables (e.g., substance use: yes/no). Studies using TFV-DP levels defined adherence consistently (i.e., TFV-DP ≥ 700 fmol/punch), with slight variations. Qualitative studies (n = 10) indicated that substance use (mainly alcohol) is related to poorer PrEP adherence. While quantitative findings to date are equivocal for alcohol, there is a pattern of findings linking stimulant use with poorer PrEP adherence. This review reveals four methodological gaps, which can be addressed in future research by: 1) use of uniform benchmarks for substance use measures, 2) prospective assessment for substance use, 3) use of continuous outcome variables wherever possible, and 4) more extensive consideration of potential confounders. Addressing these methodological gaps may help us reach more definitive conclusions regarding associations between substance use and PrEP adherence.

Nur mit Berechtigung zugänglich

CDC. PrEP | HIV Basics | HIV/AIDS | CDC [Internet]. 2020 [cited 2020 Jun 30]. Available from: https://www.cdc.gov/hiv/basics/prep.html.

CDC. HIV Basics | HIV/AIDS | CDC [Internet]. 2020 [cited 2020 Jun 30]. Available from: https://www.cdc.gov/hiv/basics/index.html.

Grant RM, Lama JR, Anderson PL, McMahan V, Liu AY, Vargas L, et al. Preexposure Chemoprophylaxis for HIV Prevention in Men who have sex with men. N Engl J Med. 2010 Dec;30(27):2587–99. 363(.CrossRef

Molina JM, Charreau I, Spire B, Cotte L, Chas J, Capitant C, et al. Efficacy, safety, and effect on sexual behaviour of on-demand pre-exposure prophylaxis for HIV in men who have sex with men: an observational cohort study. Lancet HIV. 2017 Sep 1;4(9):e402–10.

Finlayson T. Changes in HIV Preexposure Prophylaxis Awareness and Use Among Men Who Have Sex with Men — 20 Urban Areas, 2014 and 2017. MMWR Morb Mortal Wkly Rep [Internet]. 2019 [cited 2020 Jun 30];68. Available from: https://www.cdc.gov/mmwr/volumes/68/wr/mm6827a1.htm.

Coy KC, Hazen RJ, Kirkham HS, Delpino A, Siegler AJ. Persistence on HIV preexposure prophylaxis medication over a 2-year period among a national sample of 7148 PrEP users, United States, 2015 to 2017. J Int AIDS Soc [Internet]. 2019 Feb 18 [cited 2020 Jun 30];22(2). Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6378757/.

Sidebottom D, Ekström AM, Strömdahl S. A systematic review of adherence to oral pre-exposure prophylaxis for HIV – how can we improve uptake and adherence? BMC infect dis. 2018 Nov 16;18(1):581.

Maxwell S, Gafos M, Shahmanesh M. Pre-exposure Prophylaxis Use and Medication Adherence among Men who have sex with men: a systematic review of the literature. J Assoc Nurses AIDS Care. 2019 Aug;30(4):e38.CrossRefPubMed

Cook RL, Sereika SM, Hunt SC, Woodward WC, Erlen JA, Conigliaro J. Problem drinking and medication adherence among persons with HIV infection. J Gen Intern Med. 2001 Feb;16(2)(1):83–8.CrossRefPubMedPubMedCentral

10.

Gonzalez A, Barinas J, O’Cleirigh C. Substance use: impact on adherence and HIV Medical Treatment. Curr HIV/AIDS Rep. 2011 Aug 20;8(4):223.

11.

Zhang Y, Fogel JM, Guo X, Clarke W, Breaud A, Cummings V, et al. Antiretroviral drug use and HIV drug resistance among MSM and transgender women in sub-saharan Africa. AIDS. 2018 Jun 19;32(10):1301–7.

12.

Grodensky CA, Golin CE, Ochtera RD, Turner BJ. Systematic review: Effect of Alcohol Intake on Adherence to Outpatient Medication Regimens for Chronic Diseases. J Stud Alcohol Drugs. 2012 Nov 1;73(6):899–910.

13.

Kalichman SC, Amaral CM, White D, Swetsze C, Pope H, Kalichman MO, et al. Prevalence and clinical implications of interactive toxicity beliefs regarding mixing alcohol and antiretroviral therapies among people living with HIV/AIDS. AIDS Patient Care STDs. 2009 Jun;23(6):449–54.CrossRefPubMedPubMedCentral

14.

Sankar A, Wunderlich T, Neufeld S, Luborsky M. Sero-positive african Americans’ beliefs about Alcohol and their impact on anti-retroviral adherence. AIDS Behav. 2007 Mar;11(2):195–203.CrossRefPubMedPubMedCentral

15.

de Jong BC, Prentiss D, McFarland W, Machekano R, Israelski DM. Marijuana use and its association with adherence to antiretroviral therapy among HIV-infected persons with moderate to severe nausea. J Acquir Immune Defic Syndr 1999. 2005 Jan 1;38(1):43–6.

16.

Bonn-Miller MO, Oser ML, Bucossi MM, Trafton JA. Cannabis use and HIV antiretroviral therapy adherence and HIV-related symptoms. J Behav Med. 2014 Feb;37(1):1–10.CrossRefPubMed

17.

Sinha S, McCaul ME, Hutton HE, Monroe AK, Alvanzo A, Lesko C, et al. Marijuana use and HIV treatment outcomes among PWH receiving care at an urban HIV clinic. J Subst Abuse Treat. 2017 Nov;1:82:102–6.CrossRef

18.

Vidot DC, Lerner B, Gonzalez R. Cannabis Use, Medication Management and Adherence Among Persons Living with HIV. AIDS Behav. 2017 Jul 1;21(7):2005–13.

19.

Shuper PA, Joharchi N, Bogoch II, Loutfy M, Crouzat F, El-Helou P, et al. Alcohol consumption, substance use, and depression in relation to HIV Pre-Exposure Prophylaxis (PrEP) nonadherence among gay, bisexual, and other men-who-have-sex-with-men. BMC PUBLIC Health. 2020 Dec 25;20(1).

20.

Oldenburg CE, Mitty JA, Biello KB, Closson EF, Safren SA, Mayer KH, et al. Differences in Attitudes About HIV Pre-Exposure Prophylaxis Use Among Stimulant Versus Alcohol Using Men Who Have Sex with Men. AIDS Behav. 2016 Jul 1;20(7):1451–60.

21.

Storholm ED, Volk JE, Marcus JL, Silverberg MJ, Satre DD. Risk perception, sexual behaviors, and PrEP Adherence among Substance-Using men who have sex with men: a qualitative study. Prev Sci Off J Soc Prev Res. 2017 Aug;18(6):737–47.CrossRef

22.

Luehring-Jones P, Palfai TP, Tahaney KD, Maisto SA, Simons J. Pre-Exposure Prophylaxis (PrEP) use is Associated With Health Risk Behaviors among moderate- and heavy-drinking MSM. AIDS Educ Prev. 2019 Oct;31(5):452–62.CrossRefPubMed

23.

Pollock JA, Halkitis PN, Moeller RW, Solomon TM, Barton SC, Blachman-Forshay J, et al. Alcohol Use Among Young Men Who Have Sex With Men. Subst Use Misuse. 2012 Jan 1;47(1):12–21.

24.

Stall R, Paul JP, Greenwood G, Pollack LM, Bein E, Crosby GM, et al. Alcohol use, drug use and alcohol-related problems among men who have sex with men: the Urban Men’s Health Study. Addiction. 2001;96(11):1589–601.CrossRefPubMed

25.

Wong CF, Kipke MD, Weiss G. Risk factors for alcohol use, frequent use, and binge drinking among young men who have sex with men. Addict Behav. 2008 Aug 1;33(8):1012–20.

26.

Ogbuagu O, Marshall BDL, Tiberio P, Ogunbajo A, Barakat L, Montgomery M, et al. Prevalence and Correlates of Unhealthy Alcohol and Drug Use Among Men Who Have Sex with Men Prescribed HIV Pre-exposure Prophylaxis in Real-World Clinical Settings. AIDS Behav. 2019 Jan 1;23(1):190–200.

27.

Mackesy-Amiti ME, Fendrich M, Johnson TP. Prevalence of recent illicit substance use and reporting bias among MSM and other urban males. Addict Behav. 2008 Aug 1;33(8):1055–60.

28.

Reback CJ, Fletcher JB, Shoptaw S, Grella CE. Methamphetamine and other Substance Use Trends among Street-recruited men who have sex with men, from 2008 to 2011. Drug Alcohol Depend. 2013 Nov;1(1):262–5. 133(.CrossRef

29.

Sanchez TH, Zlotorzynska M, Sineath RC, Kahle E, Tregear S, Sullivan PS. National Trends in sexual behavior, Substance Use and HIV Testing among United States Men who have sex with men recruited online, 2013 through 2017. AIDS Behav. 2018 Aug;22(8):2413–25.CrossRefPubMed

30.

Solomon TM, Halkitis PN, Moeller RW, Pappas MK. Levels of methamphetamine use and addiction among gay, bisexual, and other men who have sex with men. Addict Res Theory. 2012 Feb 1;20(1):21–9.

31.

Dutra L, Stathopoulou G, Basden SL, Leyro TM, Powers MB, Otto MW. A Meta-Analytic Review of Psychosocial Interventions for Substance Use Disorders. Am J Psychiatry. 2008 Feb;165(2)(1):179–87.CrossRefPubMed

32.

Jensen CD, Cushing CC, Aylward BS, Craig JT, Sorell DM, Steele RG. Effectiveness of motivational interviewing interventions for adolescent substance use behavior change: a meta-analytic review. J Consult Clin Psychol. 2011 Aug;79(4):433–40.CrossRefPubMed

33.

Parsons JT, Golub SA, Rosof E, Holder C. Motivational Interviewing and Cognitive-Behavioral Intervention to Improve HIV Medication Adherence Among Hazardous Drinkers. J Acquir Immune Defic Syndr 1999. 2007 Dec 1;46(4):443–50.

34.

Office of Infectious Disease and HIV/AIDS Policy. Key Strategies in the Plan [Internet]. HIV.gov. 2020 [cited 2022 Mar 21]. Available from: https://www.hiv.gov/federal-response/ending-the-hiv-epidemic/key-strategies.

35.

HIV.gov. NIDA Funding Research on PrEP for HIV Prevention Among Substance. Using Populations [Internet]. HIV.gov. 2021 [cited 2022 Mar 21]. Available from: https://www.hiv.gov/blog/nida-funding-research-prep-hiv-prevention-among-substance-using-populations.

36.

Kimani M, van der Elst EM, Chirro O, Wahome E, Ibrahim F, Mukuria N, et al. “I wish to remain HIV negative”: Pre-exposure prophylaxis adherence and persistence in transgender women and men who have sex with men in coastal Kenya. PLOS ONE. 2021 Jan 19;16(1).

37.

Hojilla JC, Vlahov D, Glidden DV, Amico KR, Mehrotra M, Hance R, et al. Skating on thin ice: stimulant use and sub-optimal adherence to HIV pre-exposure prophylaxis. J Int AIDS Soc. 2018;21(3):e25103.CrossRefPubMedPubMedCentral

38.

Krakower D, Maloney KM, Powell VE, Levine K, Grasso C, Melbourne K, et al. Patterns and clinical consequences of discontinuing HIV preexposure prophylaxis during primary care. J Int AIDS Soc [Internet]. 2019 Feb 15 [cited 2020 Jun 30];22(2). Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6376610/.

39.

Study Quality Assessment Tools | NHLBI. NIH [Internet]. [cited 2021 Sep 15]. Available from: https://www.nhlbi.nih.gov/health-topics/study-quality-assessment-tools.

40.

Hammersley M. The issue of quality in qualitative research. Int J Res Method Educ. 2007 Nov 1;30(3):287–305.

41.

Hoagland B, Moreira RI, Boni RBD, Kallas EG, Madruga JV, Vasconcelos R, et al. High pre-exposure prophylaxis uptake and early adherence among men who have sex with men and transgender women at risk for HIV infection: the PrEP Brasil demonstration project. J Int AIDS Soc. 2017;20(1):21472.CrossRefPubMedPubMedCentral

42.

Liu A, Glidden DV, Anderson PL, Amico KR, McMahan V, Mehrotra M, et al. Patterns and correlates of PrEP Drug Detection among MSM and Transgender Women in the global iPrEx study. JAIDS J Acquir Immune Defic Syndr. 2014 Dec;15(5):528–37. 67(.CrossRef

43.

Spinelli MA, Scott HM, Vittinghoff E, Liu AY, Gonzalez R, Morehead-Gee A, et al. Missed Visits Associated With Future Preexposure Prophylaxis (PrEP) Discontinuation Among PrEP Users in a Municipal Primary Care Health Network. Open Forum Infect Dis. 2019 Apr 1;6(4):ofz101.

44.

Van der Elst EM, Mbogua J, Operario D, Mutua G, Kuo C, Mugo P, et al. High Acceptability of HIV Pre-exposure Prophylaxis but Challenges in Adherence and Use: Qualitative Insights from a Phase I Trial of Intermittent and Daily PrEP in At-Risk Populations in Kenya. AIDS Behav. 2013 Jul 1;17(6):2162–72.

45.

Amico KR, Miller J, Balthazar C, Serrano PA, Brothers J, Zollweg S, et al. Integrated Next Step Counseling (iNSC) for Sexual Health and PrEP Use Among Young Men Who Have Sex with Men: Implementation and Observations from ATN110/113. AIDS Behav. 2019 Jul 1;23(7):1812–23.

46.

Taylor SW, Mayer KH, Elsesser SM, Mimiaga MJ, O’Cleirigh C, Safren SA. Optimizing content for pre-exposure Prophylaxis (PrEP) counseling for men who have sex with men: perspectives of PrEP users and high-risk PrEP na < ve men. AIDS Behav. 2014 May;18(5):871–9.CrossRefPubMedCentral

47.

Gandhi M, Murnane PM, Bacchetti P, Elion R, Kolber MA, Cohen SE, et al. Hair levels of preexposure prophylaxis drugs measure adherence and are associated with renal decline among men/transwomen. AIDS. 2017 Oct;23(16):2245–51. 31(.CrossRef

48.

Hoenigl M, Hassan A, Moore DJ, Anderson PL, Corado K, Dubé MP, et al. Predictors of long-term HIV Pre-exposure Prophylaxis Adherence after Study Participation in Men who have sex with men. JAIDS J Acquir Immune Defic Syndr. 2019;81(2):166–74.CrossRefPubMed

49.

Hoenigl M, Jain S, Moore D, Collins D, Sun X, Anderson PL, et al. Substance use and adherence to HIV Preexposure Prophylaxis for Men who have sex with men. Emerg Infect Dis. 2018 Dec;24(12):2292–302.CrossRefPubMedPubMedCentral

50.

Pasipanodya EC, Jain S, Sun X, Blumenthal J, Ellorin E, Corado K, et al. Trajectories and predictors of Longitudinal Preexposure Prophylaxis Adherence among Men who have sex with men. J Infect Dis. 2018 Nov 15;218(10):1551–9.

51.

Pasipanodya EC, Li MJ, Jain S, Sun X, Tobin J, Ellorin E, et al. Greater levels of self-reported adherence to Pre-Exposure Prophylaxis (PrEP) are Associated with increased Condomless Sex among Men who have sex with men. AIDS Behav. 2020 Nov;24(11):3192–204.CrossRefPubMedPubMedCentral

52.

Songtaweesin WN, Kawichai S, Phanuphak N, Cressey TR, Wongharn P, Saisaengjan C, et al. Youth-focused strategies to promote adherence to pre-exposure prophylaxis among adolescent men who have sex with men and transgender women at-risk for HIV in Thailand. J Int AIDS Soc. 2020 Jul;23(4, SI):122–3.

53.

Selfridge M, Card KG, Lundgren K, Barnett T, Guarasci K, Drost A, et al. Exploring nurse-led HIV Pre-Exposure Prophylaxis in a community health care clinic. Public Health Nurs. 2020;37(6):871–9.CrossRefPubMed

54.

Hojilla JC, Satre DD, Glidden DV, McMahan VM, Gandhi M, Defechereux P, et al. Brief Report: Cocaine Use and Pre-exposure Prophylaxis: Adherence, Care Engagement, and Kidney Function. JAIDS J Acquir Immune Defic Syndr. 2019 May 1;81(1):78–82.

55.

O’Halloran C, Rice B, White E, Desai M, Dunn DT, McCormack S, et al. Chemsex is not a barrier to self-reported daily PrEP adherence among PROUD study participants. Int J Drug Policy. 2019 Dec;1:74:246–54.CrossRef

56.

Grov C, Rendina HJ, John SA, Parsons JT. Determining the Roles that Club Drugs, Marijuana, and Heavy Drinking Play in PrEP Medication Adherence Among Gay and Bisexual Men: Implications for Treatment and Research. AIDS Behav. 2019 May 1;23(5):1277–86.

57.

Holtz TH, Chitwarakorn A, Hughes JP, Curlin ME, Varangrat A, Li M, et al. HPTN 067/ADAPT: Correlates of Sex-Related Pre-exposure Prophylaxis Adherence, Thai Men Who Have Sex With Men, and Transgender Women, 2012–2013. JAIDS J Acquir Immune Defic Syndr. 2019 Oct 1;82(2):e18.

58.

Mannheimer S, Hirsch-Moverman Y, Franks J, Loquere A, Hughes JP, Li M, et al. Factors Associated with Sex-Related pre-exposure Prophylaxis Adherence among Men who have sex with men in New York City in HPTN 067. JAIDS J Acquir Immune Defic Syndr. 2019 Apr 15;80(5):551–8.

59.

Wray TB, Chan PA, Kahler CW, Simpanen EM, Liu T, Mayer KH. Vulnerable Periods: Characterizing Patterns of Sexual Risk and Substance Use During Lapses in Adherence to HIV Pre-exposure Prophylaxis Among Men Who Have Sex With Men. JAIDS J Acquir Immune Defic Syndr. 2019 Mar 1;80(3):276–83.

60.

Landovitz RJ, Beymer M, Kofron R, Amico KR, Psaros C, Bushman L, et al. Plasma tenofovir levels to support adherence to TDF/FTC Preexposure Prophylaxis for HIV Prevention in MSM in Los Angeles, California. JAIDS J Acquir Immune Defic Syndr. 2017 Dec;15(5):501–11. 76(.CrossRef

61.

Grinsztejn B, Hoagland B, Moreira RI, Kallas EG, Madruga JV, Goulart S, et al. Retention, engagement, and adherence to pre-exposure prophylaxis for men who have sex with men and transgender women in PrEP Brasil: 48 week results of a demonstration study. Lancet HIV. 2018 Mar 1;5(3):e136–45.

62.

Wang H, Zhang J, Chu Z, Hu Q, Dong W, Huang X, et al. Risk-taking behaviors and adherence to HIV Pre-Exposure Prophylaxis in users of Geosocial networking apps: Real-World, Multicenter Study. J Med Internet Res. 2020 Oct;14(10):e22388. 22(.CrossRef

63.

Grant RM, Anderson PL, McMahan V, Liu A, Amico KR, Mehrotra M, et al. Uptake of pre-exposure prophylaxis, sexual practices, and HIV incidence in men and transgender women who have sex with men: a cohort study. Lancet Infect Dis. 2014 Sep 1;14(9):820–9.

64.

Vaccher SJ, Marzinke MA, Templeton DJ, Haire BG, Ryder N, McNulty A, et al. Predictors of Daily Adherence to HIV Pre-exposure Prophylaxis in Gay/Bisexual Men in the PRELUDE Demonstration Project. AIDS Behav. 2019 May 1;23(5):1287–96.

65.

Castillo-Mancilla J, Seifert S, Campbell K, Coleman S, McAllister K, Zheng JH, et al. Emtricitabine-Triphosphate in dried blood spots as a marker of recent dosing. Antimicrob Agents Chemother. 2016;60(11):6692–7.CrossRefPubMedPubMedCentral

66.

Seekaew P, Nguyen E, Sungsing T, Jantarapakde J, Pengnonyang S, Trachunthong D, et al. Correlates of nonadherence to key population-led HIV pre-exposure prophylaxis services among Thai men who have sex with men and transgender women. BMC Public Health. 2019 Mar 21;19(1):328.

67.

Mugo PM, Sanders EJ, Mutua G, van der Elst E, Anzala O, Barin B, et al. Understanding adherence to Daily and intermittent regimens of oral HIV pre-exposure Prophylaxis among Men who have sex with men in Kenya. AIDS Behav. 2015 May;19(5):794–801.CrossRefPubMed

68.

Tangmunkongvorakul A, Chariyalertsak S, Amico KR, Saokhieo P, Wannalak V, Sangangamsakun T, et al. Facilitators and barriers to medication adherence in an HIV prevention study among men who have sex with men in the iPrEx study in Chiang Mai, Thailand. AIDS Care. 2013 Aug 1;25(8):961–7.

69.

Liu AY, Cohen SE, Vittinghoff E, Anderson PL, Doblecki-Lewis S, Bacon O, et al. Preexposure Prophylaxis for HIV infection Integrated with Municipal- and community-based sexual Health Services. JAMA Intern Med. 2016 Jan;176(1)(1):75–84.CrossRefPubMedPubMedCentral

70.

Velloza J, Bacchetti P, Hendrix CW, Murnane P, Hughes JP, Li M, et al. Short- and Long-Term Pharmacologic Measures of HIV Pre-exposure Prophylaxis Use Among High-Risk Men Who Have Sex With Men in HPTN 067/ADAPT. J Acquir Immune Defic Syndr 1999. 2019 01;82(2):149–58.

71.

Wu D, Tao H, Dai J, Liang H, Huang A, Zhong X. Study on Pre-Exposure Prophylaxis Regimens among Men who have sex with men: a prospective cohort study. Int J Environ Res Public Health. 2019 Jan;16(24):4996.CrossRefPubMedPubMedCentral

72.

Blashill AJ, Brady JP, Rooney BM, Rodriguez-Diaz CE, Horvath KJ, Blumenthal J, et al. Syndemics and the PrEP Cascade: Results from a Sample of Young Latino Men Who Have Sex with Men. Arch Sex Behav. 2020 Jan 1;49(1):125–35.

73.

Liu AY, Hessol NA, Vittinghoff E, Amico KR, Kroboth E, Fuchs J, et al. Medication Adherence among Men who have sex with men at risk for HIV infection in the United States: implications for Pre-Exposure Prophylaxis implementation. AIDS Patient Care STDs. 2014 Nov;14;28(12):622–7.CrossRef

74.

Egan JE, Ho K, Stall R, Drucker MT, Tappin R, Hendrix CW, et al. Feasibility of short-term PrEP Uptake for Men who have sex with men with episodic periods of increased HIV risk. JAIDS-J Acquir IMMUNE Defic Syndr. 2020 Aug 15;84(5):508–13.

75.

Martin M, Vanichseni S, Suntharasamai P, Sangkum U, Mock PA, Leethochawalit M, et al. The impact of adherence to preexposure prophylaxis on the risk of HIV infection among people who inject drugs. AIDS. 2015 Apr;24(7):819–24. 29(.CrossRef

76.

Okafor CN, Hucks-Ortiz C, Hightow-Weidman LB, Magnus M, Emel L, Beauchamp G, et al. Brief Report: Associations Between Self-Reported Substance Use Behaviors and PrEP Acceptance and Adherence Among Black MSM in the HPTN 073 Study. J Acquir Immune Defic Syndr 1999. 2020 Sep 1;85(1):23–9.

77.

Hoenigl M, Morgan E, Franklin D, Anderson PL, Pasipanodya E, Dawson M, et al. Self-initiated continuation of and adherence to HIV pre-exposure prophylaxis (PrEP) after PrEP demonstration project roll-off in men who have sex with men: associations with risky decision making, impulsivity/disinhibition, and sensation seeking. J Neurovirol. 2019 Jun 1;25(3):324–30.

78.

Goodman-Meza D, Beymer MR, Kofron RM, Amico KR, Psaros C, Bushman LR, et al. Effective use of pre-exposure prophylaxis (PrEP) Among stimulant users with multiple condomless sex partners: a longitudinal study of men who have sex with men in Los Angeles. AIDS Care. 2019 Oct 3;31(10):1228–33.

79.

Robles G, Sauermilch D, Gandhi M, Starks TJ. PrEP demonstration project showed Superior Adherence with Tenofovir Alafenamide/Emtricitabine compared to Tenofovir Disoproxil Fumarate/Emtricitabine in a sample of partnered sexual minority men. AIDS Behav. 2021;25(4):1299–305.CrossRefPubMed

80.

Chemnasiri T, Varangrat A, Amico KR, Chitwarakorn A, Dye BJ, Grant RM, et al. Facilitators and barriers affecting PrEP adherence among thai men who have sex with men (MSM) in the HPTN 067/ADAPT study. AIDS Care. 2020 Feb;32(2):249–54.CrossRefPubMed

81.

Franks J, Hirsch-Moverman Y, Loquere AS, Amico KR, Grant RM, Dye BJ, et al. Sex, PrEP, and Stigma: Experiences with HIV Pre-exposure Prophylaxis Among New York City MSM Participating in the HPTN 067/ADAPT Study. AIDS Behav. 2018 Apr 1;22(4):1139–49.

82.

Chai PR, Goodman G, Bustamante M, Mendez L, Mohamed Y, Mayer KH, et al. Design and delivery of real-time Adherence Data to Men who have sex with men using antiretroviral pre-exposure Prophylaxis via an Ingestible Electronic Sensor. AIDS Behav. 2021 Jun;25(6)(1):1661–74.CrossRefPubMed

83.

Closson EF, Mitty JA, Malone J, Mayer KH, Mimiaga MJ. Exploring strategies for PrEP adherence and dosing preferences in the context of sexualized recreational drug use among MSM: a qualitative study. AIDS Care. 2018 Feb;30(2):191–8.CrossRefPubMed

84.

Spinelli MA, Laborde N, Kinley P, Whitacre R, Scott HM, Walker N, et al. Missed opportunities to prevent HIV infections among pre-exposure prophylaxis users: a population-based mixed methods study, San Francisco, United States. J Int AIDS Soc. 2020;23(4):e25472.CrossRefPubMedPubMedCentral

85.

Mannes ZL, Burrell LE, Ferguson EG, Zhou Z, Lu H, Somboonwit C, et al. The association of therapeutic versus recreational marijuana use and antiretroviral adherence among adults living with HIV in Florida. Patient Prefer Adherence. 2018 Jul 27;12:1363–72.

86.

Edeza A, Karina Santamaria E, Valente PK, Gomez A, Ogunbajo A, Biello K. Experienced barriers to adherence to pre-exposure prophylaxis for HIV prevention among MSM: a systematic review and meta-ethnography of qualitative studies. AIDS Care. 2021 Jun 3;33(6):697–705.

87.

Mayer KH, Agwu A, Malebranche D. Barriers to the Wider Use of Pre-exposure Prophylaxis in the United States: A Narrative Review. Adv Ther. 2020 May 1;37(5):1778–811.

88.

Steinmetz H, Knappstein M, Ajzen I, Schmidt P, Kabst R. How Effective are Behavior Change Interventions Based on the Theory of Planned Behavior? Z Für Psychol. 2016 Jul 1;224(3):216–33.

89.

Najt P, Fusar-Poli P, Brambilla P. Co-occurring mental and substance abuse disorders: a review on the potential predictors and clinical outcomes. Psychiatry Res. 2011 Apr 30;186(2):159–64.

90.

Narvaez JCM, Jansen K, Pinheiro RT, Kapczinski F, Silva RA, Pechansky F, et al. Psychiatric and substance-use comorbidities associated with lifetime crack cocaine use in young adults in the general population. Compr Psychiatry. 2014 Aug 1;55(6):1369–76.

91.

Wilson IB, Lee Y, Michaud J, Fowler FJ, Rogers WH. Validation of a New Three-Item Self-Report measure for Medication Adherence. AIDS Behav. 2016 Nov;20(11)(1):2700–8.CrossRefPubMedPubMedCentral

92.

Myers JJ, Kang Dufour MS, Koester KA, Udoh I, Frazier R, Packard R, et al. Adherence to PrEP Among Young Men Who Have Sex With Men Participating in a Sexual Health Services Demonstration Project in Alameda County, California. JAIDS J Acquir Immune Defic Syndr. 2019 Aug 1;81(4):406–13.

93.

Wheeler DP, Fields SD, Beauchamp G, Chen YQ, Emel LM, Hightow-Weidman L, et al. Pre-exposure prophylaxis initiation and adherence among black men who have sex with men (MSM) in three US cities: results from the HPTN 073 study. J Int AIDS Soc. 2019;22(2):e25223.CrossRefPubMedPubMedCentral

Titel: Substance Use and Adherence to HIV Pre-Exposure Prophylaxis in Studies Enrolling Men Who Have Sex with Men and Transgender Women: A Systematic Review
verfasst von: Nioud Mulugeta Gebru
Shantrel S. Canidate
Yiyang Liu
Sage E. Schaefer
Emmely Pavila
Robert L. Cook
Robert F. Leeman
Publikationsdatum: 20.12.2022
Verlag: Springer US
Erschienen in: AIDS and Behavior / Ausgabe 7/2023
Print ISSN: 1090-7165
Elektronische ISSN: 1573-3254
DOI: https://doi.org/10.1007/s10461-022-03948-3

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

^{Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag}

Kostenlos registrieren

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Live-Webinar "Urologie und Sexualmedizin in der Praxis"

Springer Medizin

Substance Use and Adherence to HIV Pre-Exposure Prophylaxis in Studies Enrolling Men Who Have Sex with Men and Transgender Women: A Systematic Review

Abstract

Leitlinien kompakt für die Innere Medizin

Neu im Fachgebiet Innere Medizin

Erhebliches Risiko für Kehlkopfkrebs bei mäßiger Dysplasie

Nach Herzinfarkt mit Typ-1-Diabetes schlechtere Karten als mit Typ 2?

15% bedauern gewählte Blasenkrebs-Therapie

Costims – das nächste heiße Ding in der Krebstherapie?

Update Innere Medizin

Live-Webinar "Urologie und Sexualmedizin in der Praxis"

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 7/2023

Clinical and Behavioral Outcomes for Transgender Women Engaged in HIV Care: Comparisons to Cisgender Men and Women in the Centers for AIDS Research Network of Integrated Clinical Systems (CNICS) Cohort

Age-varying Associations of Depressive Symptoms and Heavy Episodic Drinking Throughout Adulthood Among People with HIV and Receiving care in Cameroon Within a National “treat all” Policy

Young Adult Perspectives on Sex, Dating, and PrEP Use During the Pandemic and Improving the Future of PrEP Care

Experiences of Black Women in the United States Along the PrEP Care Continuum: A Scoping Review

Acceptability and Feasibility of Online, Asynchronous Photovoice with Key Populations and People Living with HIV

The Relationship Between Alcohol and Drug Use, Compulsive Sexual Behavior, and Condomless Anal Sex in Men Who have Sex with Men: Analysis of Retrospectively-Reported Sexual Behavior

Leitlinien kompakt für die Innere Medizin

Neu im Fachgebiet Innere Medizin

Erhebliches Risiko für Kehlkopfkrebs bei mäßiger Dysplasie

Nach Herzinfarkt mit Typ-1-Diabetes schlechtere Karten als mit Typ 2?

15% bedauern gewählte Blasenkrebs-Therapie

Costims – das nächste heiße Ding in der Krebstherapie?

Update Innere Medizin